SE0203753D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0203753D0
SE0203753D0 SE0203753A SE0203753A SE0203753D0 SE 0203753 D0 SE0203753 D0 SE 0203753D0 SE 0203753 A SE0203753 A SE 0203753A SE 0203753 A SE0203753 A SE 0203753A SE 0203753 D0 SE0203753 D0 SE 0203753D0
Authority
SE
Sweden
Prior art keywords
compounds
phenyl
active compounds
membered heteroaromatic
heteroaromatic ring
Prior art date
Application number
SE0203753A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203753A priority Critical patent/SE0203753D0/xx
Publication of SE0203753D0 publication Critical patent/SE0203753D0/xx
Priority to TW092134210A priority patent/TW200505905A/zh
Priority to ARP030104528A priority patent/AR042343A1/es
Priority to SI200330850T priority patent/SI1575942T1/sl
Priority to PT03781206T priority patent/PT1575942E/pt
Priority to ES03781206T priority patent/ES2285221T3/es
Priority to DE60313658T priority patent/DE60313658T2/de
Priority to KR1020057011135A priority patent/KR20050084362A/ko
Priority to US10/539,545 priority patent/US7595321B2/en
Priority to EP03781206A priority patent/EP1575942B1/en
Priority to CA002508045A priority patent/CA2508045A1/en
Priority to NZ540450A priority patent/NZ540450A/en
Priority to PCT/SE2003/001957 priority patent/WO2004055009A1/en
Priority to CNB2003801064833A priority patent/CN100360522C/zh
Priority to JP2004560225A priority patent/JP2006512337A/ja
Priority to DK03781206T priority patent/DK1575942T3/da
Priority to AT03781206T priority patent/ATE361291T1/de
Priority to AU2003287137A priority patent/AU2003287137B2/en
Priority to BR0317299-6A priority patent/BR0317299A/pt
Priority to MXPA05006244A priority patent/MXPA05006244A/es
Priority to ZA200504874A priority patent/ZA200504874B/en
Priority to NO20053459A priority patent/NO20053459L/no
Priority to HK06100841A priority patent/HK1080854A1/xx
Priority to CY20071100890T priority patent/CY1106709T1/el
Priority to US12/568,266 priority patent/US20100087396A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0203753A 2002-12-17 2002-12-17 New compounds SE0203753D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0203753A SE0203753D0 (sv) 2002-12-17 2002-12-17 New compounds
TW092134210A TW200505905A (en) 2002-12-17 2003-12-04 New compounds
ARP030104528A AR042343A1 (es) 2002-12-17 2003-12-09 Derivados de pirazina que presentan efecto inhibidor selectivo sobre gsk3, proceso de preparacion y formulaciones farmaceuticas que los contienen
MXPA05006244A MXPA05006244A (es) 2002-12-17 2003-12-15 Compuestos novedosos que tienen un efecto de inhibicion selectiva en gsk3.
CA002508045A CA2508045A1 (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting efect at gsk3
JP2004560225A JP2006512337A (ja) 2002-12-17 2003-12-15 Ｇｓｋ３で選択的な阻害作用を示す新規な化合物
ES03781206T ES2285221T3 (es) 2002-12-17 2003-12-15 Compuestos que tienen un efecto inhibidor selectivo en gsk3.
DE60313658T DE60313658T2 (de) 2002-12-17 2003-12-15 Verbindungen mit selektiver inhibierender wirkung an gsk3
KR1020057011135A KR20050084362A (ko) 2002-12-17 2003-12-15 Ｇｓｋ3에서 선택적 저해 효과를 갖는 신규 화합물
US10/539,545 US7595321B2 (en) 2002-12-17 2003-12-15 Compounds having selective inhibiting effect at GSK3
EP03781206A EP1575942B1 (en) 2002-12-17 2003-12-15 compounds having selective inhibiting efect at gsk3
SI200330850T SI1575942T1 (sl) 2002-12-17 2003-12-15 Spojine s selektivnim inhibicijskim učinkom pri GSK3
NZ540450A NZ540450A (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting effect at GSK3
PCT/SE2003/001957 WO2004055009A1 (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting efect at gsk3
CNB2003801064833A CN100360522C (zh) 2002-12-17 2003-12-15 对gsk3具有选择性抑制作用的新型化合物
PT03781206T PT1575942E (pt) 2002-12-17 2003-12-15 Compostos possuindo efeito de inibição selectivo sobre a gsk3
DK03781206T DK1575942T3 (da) 2002-12-17 2003-12-15 Forbindelser med selektivt inhiberende virkning ved GSK3
AT03781206T ATE361291T1 (de) 2002-12-17 2003-12-15 Verbindungen mit selektiver inhibierender wirkung an gsk3
AU2003287137A AU2003287137B2 (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting effect at GSK3
BR0317299-6A BR0317299A (pt) 2002-12-17 2003-12-15 Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, processo para a preparação de um composto, e, uso dos intermediários
ZA200504874A ZA200504874B (en) 2002-12-17 2005-06-14 Novel compounds having selective inhibiting effect at GSK3
NO20053459A NO20053459L (no) 2002-12-17 2005-07-15 Nye forbindelser med selektiv inhiberende effekt av GSK3
HK06100841A HK1080854A1 (en) 2002-12-17 2006-01-18 Compounds having selective inhibiting efect at gsk3
CY20071100890T CY1106709T1 (el) 2002-12-17 2007-07-04 Νεες ενωσεις που εχουν επιλεκτικη δραση αναστολης στην gsk3
US12/568,266 US20100087396A1 (en) 2002-12-17 2009-09-28 Novel Compounds Having Selective Inhibiting Effect at GSK3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203753A SE0203753D0 (sv) 2002-12-17 2002-12-17 New compounds

Publications (1)

Publication Number Publication Date
SE0203753D0 true SE0203753D0 (sv) 2002-12-17

Family

ID=20289906

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203753A SE0203753D0 (sv) 2002-12-17 2002-12-17 New compounds

Country Status (23)

Country Link
US (2) US7595321B2 (es)
EP (1) EP1575942B1 (es)
JP (1) JP2006512337A (es)
KR (1) KR20050084362A (es)
CN (1) CN100360522C (es)
AR (1) AR042343A1 (es)
AT (1) ATE361291T1 (es)
AU (1) AU2003287137B2 (es)
BR (1) BR0317299A (es)
CA (1) CA2508045A1 (es)
CY (1) CY1106709T1 (es)
DE (1) DE60313658T2 (es)
DK (1) DK1575942T3 (es)
ES (1) ES2285221T3 (es)
HK (1) HK1080854A1 (es)
MX (1) MXPA05006244A (es)
NO (1) NO20053459L (es)
NZ (1) NZ540450A (es)
PT (1) PT1575942E (es)
SE (1) SE0203753D0 (es)
TW (1) TW200505905A (es)
WO (1) WO2004055009A1 (es)
ZA (1) ZA200504874B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2009130317A1 (en) * 2008-04-24 2009-10-29 Abbott Gmbh & Co. Kg 1- (7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
EP2438041A4 (en) * 2009-06-01 2012-11-21 Merck Sharp & Dohme PYRAZINE-carboxamide-orexin receptor Antagonist
US8198285B2 (en) 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
HRP20211868T1 (hr) 2016-07-20 2022-03-04 Novartis Ag Derivati aminopiridina i njihova uporaba kao selektivnih inhibitora za alk-2
BR112022009710A2 (pt) 2019-11-22 2022-08-09 Incyte Corp Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
AU2021292484A1 (en) 2020-06-16 2023-01-19 Incyte Corporation ALK2 inhibitors for the treatment of anemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472823A (en) 1992-01-20 1995-12-05 Hitachi Chemical Co., Ltd. Photosensitive resin composition
JPH10152622A (ja) 1996-11-26 1998-06-09 Dainippon Ink & Chem Inc ジスアゾ化合物およびジスアゾ顔料
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
KR20030031886A (ko) * 2000-02-16 2003-04-23 뉴로젠 코포레이션 치환된 아릴피라진
BR0108974A (pt) * 2000-03-07 2003-06-03 Aventis Pharma Gmbh 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1406884A1 (en) * 2001-05-11 2004-04-14 Biovitrum Ab Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
CY1106709T1 (el) 2012-05-23
CN100360522C (zh) 2008-01-09
US20060116385A1 (en) 2006-06-01
HK1080854A1 (en) 2006-05-04
DK1575942T3 (da) 2007-09-03
CN1726210A (zh) 2006-01-25
US7595321B2 (en) 2009-09-29
BR0317299A (pt) 2005-11-08
US20100087396A1 (en) 2010-04-08
WO2004055009A8 (en) 2005-06-30
AU2003287137A1 (en) 2004-07-09
DE60313658D1 (de) 2007-06-14
EP1575942B1 (en) 2007-05-02
NZ540450A (en) 2007-10-26
JP2006512337A (ja) 2006-04-13
DE60313658T2 (de) 2008-01-10
MXPA05006244A (es) 2005-08-19
AU2003287137B2 (en) 2007-07-05
EP1575942A1 (en) 2005-09-21
PT1575942E (pt) 2007-07-09
CA2508045A1 (en) 2004-07-01
TW200505905A (en) 2005-02-16
AR042343A1 (es) 2005-06-15
NO20053459L (no) 2005-08-12
KR20050084362A (ko) 2005-08-26
WO2004055009A1 (en) 2004-07-01
ES2285221T3 (es) 2007-11-16
ZA200504874B (en) 2006-04-26
ATE361291T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
WO2004055005A8 (en) Novel compounds having selective inhibiting effect at gsk3
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
SE0102438D0 (sv) New compounds
SE0102439D0 (sv) New compounds
AP2001002299A0 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents.
MA26880A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation.
PA8591701A1 (es) Derivados de pirrolopirimidina
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
AR033359A1 (es) Compuesto amidino, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para inhibir la sintesis de oxido nitrico
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
NO20053459L (no) Nye forbindelser med selektiv inhiberende effekt av GSK3
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
SE9701304D0 (sv) Compounds
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
ATE360428T1 (de) Analgetisches arzneimittel
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
TW200420292A (en) Benzofuran derivative
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DK1147105T3 (da) Optisk aktivt pyridyl-4H-1,2,4-oxadiazinderivat og anvendelse af dette til behandling af karsygdomme
SE0004101D0 (sv) New use
ATE250610T1 (de) Kaliumkanal-blockierende mittel
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
HUP0203476A2 (en) Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same